
Lieu de naissance
ARALIK
Langues
ANGLAIS
2024 - 2025
Hôpital İstinye Üniversitesi Bahçeşehir
2019 - 2024
Hôpital Régional d'Enseignement et de Recherche de Van
2014 - 2014
Hôpital d'État de Silopi
2007 - 2008
Hôpital d'État de Van
2018
Université d'Istanbul, Faculté de Médecine d'Istanbul, Rhumatologie
2014
Université d'Istanbul, Faculté de Médecine d'Istanbul, Médecine Interne
2014
Université d'Istanbul, Faculté de Médecine d'Istanbul, Médecine Interne
2010
Université Atatürk, Faculté de Médecine, Cardiologie - Assistant de Recherche
2007
Université Uludağ, Faculté de Médecine
1. Oğuz E, Bektaş M. Characteristics of patients with Behçet disease from the Van province, eastern Turkey: Definition of disease clusters in a tertiary referral center. J Clin Rheumatol. 2023. doi:10.1097/RHU.0000000000001996
2. Oğuz E, et al. Characteristics and course of patients with AA amyloidosis: Single centre experience with 174 patients from Turkey. Rheumatology (Oxford). 2024;63(2):319-328. doi:10.1093/rheumatology/kead465
3. Oğuz E, et al. Utility of positron emission tomography as a new tool for muscle involvement in patients with idiopathic inflammatory myositis: A controlled study. Clin Exp Rheumatol. 2024;42(2):358-366. doi:10.55563/clinexprheumatol/9u122p
4. Bektaş M, Özer MD, Oğuz E. The safety and efficacy of TNF inhibitors in patients with Behçet’s disease: Retrospective study from eastern Turkey. Clin Immunol. 2024;264:110239. doi:10.1016/j.clim.2024.110239
5. Oğuz E, Koca N, Bektaş M. Presence of myositis-specific autoantibodies may predict favorable outcomes to rituximab in patients with idiopathic inflammatory myositis: Retrospective observational study. Mod Rheumatol. 2025 (ahead of print). doi:10.1093/mr/roaf097
6. Oğuz E, et al. Chronic oxcarbazepine intoxication in a patient with primary antiphospholipid syndrome on maintenance haemodialysis. J Clin Pharm Ther. 2022;47(2):257-259. doi:10.1111/jcpt.13504
7. Oğuz E, et al. Activation-induced cytidine deaminase expression in patients with chronic myeloid leukemia Experimed. 2022;12(3):155-159
8. Oğuz E, et al. Üçüncü basamak bir hastanede takip edilen COVID-19 olgularında immünosüpresif tedavi uygulanan hastaların değerlendirilmesi. Klimik Dergisi. 2022
PRÉSENTATIONS À DES CONGRÈS INTERNATIONAUX (ACR)
9. Oğuz E, et al. Classification of idiopathic inflammatory myopathies: Assessment according to 2017 ACR/EULAR criteria. Arthritis Rheumatol. 2018;70(Suppl 9)
10. Oğuz E, et al. Favourable response to rituximab in IgG4-related disease: Long-term follow-up. Arthritis Rheumatol. 2018;70(Suppl 9)
11. Bektaş M, et al., Oğuz E. PET imaging in idiopathic inflammatory myositis: A case-control study. Arthritis Rheumatol. 2021;73(Suppl 9)
12. Toz B, et al., Oğuz E. IL-1 inhibitors in FMF-associated amyloidosis: Retrospective analysis. Arthritis Rheumatol. 2016;68(Suppl 10